PBM Stock Risk & Deep Value Analysis
Psyence Biomedical Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PBM Stock
We analyzed Psyence Biomedical Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PBM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is PBM Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
Competitive Risk
High
Execution Risk
High
Regulatory Risk
High
What Are the Red Flags for PBM?
- âš
Negative or inconclusive clinical trial results (any time)
- âš
Failure to secure adequate future funding, leading to operational delays or cessation (ongoing)
- âš
Increased regulatory scrutiny or unfavorable policy changes (ongoing)
- âš
Key competitor achieves significant clinical or commercial breakthrough (ongoing)
Unlock PBM Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Psyence Biomedical Ltd (PBM) Do?
Market Cap
$1.87M
Sector
Healthcare
Industry
Biotechnology
Employees
12
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Visit Psyence Biomedical Ltd WebsiteIs PBM Stock Undervalued?
Unlock the full AI analysis for PBM
Get the complete DVR score, risk analysis, and more
Does PBM Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is currently nascent and highly fragile, depending entirely on successful clinical trials, regulatory approvals, and strong patent protection. It is subject to significant erosion from clinical failures, IP challenges, and superior competitor offerings.
Moat Erosion Risks
- •Clinical trial failures or inconclusive results preventing regulatory approval.
- •Competitors developing more effective or safer compounds/therapies.
- •Intellectual property challenges or expiration of patents.
- •Changes in regulatory landscape favoring generic or alternative treatments.
PBM Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive PBM Stock Higher?
Near-Term (0-6 months)
- •Phase 1 or 2 clinical trial updates (Q2/Q3 2026)
- •New intellectual property filings or patent grants (ongoing)
- •Announcements of key scientific advisory board additions (Q2 2026)
Medium-Term (6-18 months)
- •Initiation of next phase clinical trials (e.g., Phase 2b or 3) (Q4 2026 - Q2 2027)
- •Strategic partnership or licensing agreement announcements (H2 2027)
- •Further clarity on regulatory pathways for psychedelic therapies in key markets (ongoing)
Long-Term (18+ months)
- •Successful Phase 3 trial completion and data readout (2028-2029)
- •Market approval of a novel psychedelic-assisted therapy (2029+)
- •Establishment of a scalable therapy delivery model and clinics (2029+)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PBM?
- ✓
Positive clinical trial data readouts and progression to advanced phases.
- ✓
Successful capital raises at favorable terms, reducing dilution risk.
- ✓
Key partnerships for research, development, or commercialization.
- ✓
Material changes in cash burn rate or cash runway indicating financial distress.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PBM (Psyence Biomedical Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
